Fycompa

Publications

Study 305

Study 305 was a randomised, double-blind, placebo-controlled study conducted in Europe, Australia and Asia, to evaluate the efficacy and safety of perampanel at higher daily doses of 8 and 12 mg given as an adjunctive therapy in patients with partial-onset seizures 12 years and older. Patients started on 2 mg of perampanel once daily, then remained on 2 mg, or increased dosage weekly in 2 mg increments to their randomised doses of 8 mg or 12 mg once daily.

Reference: French J, Krauss G, Steinhoff B et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: Results of a randomized global phase III study 305. Epilepsia 2013; 54(1): 117-125

Click here to download Study 305:
https://eorder.sheridan.com/3_0/app/orders/4169/article.php